Compare BABA & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BABA | JNJ |
|---|---|---|
| Founded | 1999 | 1886 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.5B | 449.6B |
| IPO Year | 2014 | 1944 |
| Metric | BABA | JNJ |
|---|---|---|
| Price | $150.85 | $204.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | $188.69 | ★ $209.27 |
| AVG Volume (30 Days) | ★ 9.4M | 7.5M |
| Earning Date | 02-19-2026 | 01-21-2026 |
| Dividend Yield | 0.70% | ★ 2.54% |
| EPS Growth | 51.05 | ★ 71.26 |
| EPS | 7.35 | ★ 10.35 |
| Revenue | ★ $142,158,529,239.00 | $92,149,000,000.00 |
| Revenue This Year | $6.30 | $6.61 |
| Revenue Next Year | $11.23 | $5.33 |
| P/E Ratio | $20.55 | ★ $19.75 |
| Revenue Growth | ★ 5.21 | 5.08 |
| 52 Week Low | $80.06 | $140.68 |
| 52 Week High | $192.67 | $215.19 |
| Indicator | BABA | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 46.80 |
| Support Level | $145.27 | $200.91 |
| Resistance Level | $155.29 | $208.98 |
| Average True Range (ATR) | 3.21 | 2.81 |
| MACD | 0.58 | -0.76 |
| Stochastic Oscillator | 49.03 | 36.39 |
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China retail e-commerce platform is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China wholesale e-commerce, international retail and wholesale e-commerce, local consumer services, travel services, cloud computing, digital media and entertainment, Cainiao logistics services, and other businesses.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.